Skip to main content
Premium Trial:

Request an Annual Quote

Tripos s Revenues Slide 16 Percent, Earnings Increase in Q2

NEW YORK, July 28 (GenomeWeb News) - Tripos yesterday reported a drop in revenues amidst increased earnings for the second quarter of 2005.


Tripos' revenues were $13.4 million, down 16 percent from last year's $15.9 million during the same period. This decrease was "primarily due to the anticipated decline for the current stage of our Pfizer chemical file enrichment contract," said president and CEO John McAlister in a statement.


Research and development costs fell to $2 million, down from $2.5 million during the year-ago period.


Net income for the quarter was $1.7 million, or $.17 per share, up from $156,000, or $.02 per share, during last year's second quarter. Most of these earnings came from an income tax benefit of nearly $2 million.


As of June 30, Tripos had $6.2 million in cash and cash equivalents.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.